Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/22/2025

Rabies Vaccine Characteristics

Vaccine Composition

  • The Centers for Disease Control and Prevention recommends the use of inactivated rabies vaccines, including Human Diploid Cell Vaccine (HDCV), Purified Chick Embryo Cell Vaccine (PCECV), and Rabies Vaccine Adsorbed (RVA), which are prepared from killed rabies virus and inactivated with betapropiolactone 2, 3, 4
  • The American Academy of Pediatrics and the Centers for Disease Control and Prevention support the use of HDCV, PCECV, and RVA, which are inactivated vaccines that contain killed rabies virus 2, 3, 4

Clinical Implications

  • The Centers for Disease Control and Prevention states that inactivated rabies vaccines can be safely administered to immunocompromised patients, including solid-organ transplant recipients, when rabies exposure occurs 5
  • The World Health Organization notes that inactivated rabies vaccines cannot cause rabies infection since the virus is completely killed during the manufacturing process 1, 2
  • The Advisory Committee on Immunization Practices recommends that inactivated rabies vaccines require multiple doses to generate adequate immune response, as inactivated vaccines generally produce weaker immunity than live vaccines 1
  • The Centers for Disease Control and Prevention advises that inactivated rabies vaccines work by inducing active antibody production over 7-10 days, which is why rabies immune globulin (passive immunity) must be given concurrently for postexposure prophylaxis 1, 6